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OBJECTIVES:To examine the association ofmissed diagnoseswith patient, ED, and
hospital characteristics using administrative dataMETHODS:We conducted a ret-
rospective analysis ofmissed stroke diagnosis using linked inpatient discharge and
ED visit records from the 2009 HCUP State Inpatient Databases (SID) and 2008 and
2009 HCUP State Emergency Department Databases (SEDD). This study was set in
inpatient facilities and emergency departments in nine states (CA, FL, HI, MA, MO,
NE, NY, SC, TN). We identified patients who were admitted for stroke and had a
“treat and release” ED visit in the prior 30 days for a benign headache or dizziness.
We excluded stroke admissions for patients under 18 years and for certain other
admissions (not occurring through the ED; occurring in facilities with fewer than
seven total stroke admissions during 2009; and with missing covariate values).
RESULTS: Males (OR0.75; p 0.001) and older individuals (compared to 18-44,
45-64: OR0.43; 65-74: OR0.28; 75: OR0.19; p.001) had lower odds, while
Blacks (OR1.17; p.03), Asian/Pacific Islanders (OR1.29; p0.03), and Hispanics
(OR1.30; p0.001) had higher odds of a missed stroke diagnosis. Medicare
(OR0.66; p .001) and Medicaid (OR0.70; p 0.001) patients had lower odds of a
missed diagnosis compared to privately-insured patients. Non-teaching hospitals
(OR1.45; p0.002) and hospitals with low volume (OR1.57; p0.008) had higher
odds of a missed diagnosis. CONCLUSIONS: Physicians in the ED who are evaluat-
ing patients with headache and dizziness might want to be more attuned to the
possibility of stroke in women, younger patients, and nonwhite patients.
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OBJECTIVES: Hyperlipidemic patients at risk of cardiovascular (CV) events who
receive simvastatin or atorvastatin as a first-line treatment may be less likely to
meet low-density lipoprotein cholesterol (LDL-C) goals and thus more likely to
experience CV events than patients who initiate on rosuvastatin. A deterministic
model was developed to estimate the budget impact over 3 years of initiating
high-risk patients in a hypothetical managed health care (MHC) plan on rosuvas-
tatin rather than simvastatin or atorvastatin. METHODS: Among 1,000,000 health
plan members aged 18 years, 1,000 patients (0.1%) were assumed to initiate
statins. The average baseline LDL-C level was 160mg/dL. Two scenarios weremod-
eled: in scenario 1 all patients were initiated on simvastatin or atorvastatin and
titrated to a higher dose, or switched to atorvastatin (if initiated on simvastatin) or
rosuvastatin; in scenario 2, 50% of the 530 high-risk patients – based on National
Cholesterol Education Program (NCEP) guidelines – were initiated on rosuvastatin.
Product labeling, clinical trial results, national prescription claims data, and pub-
lished literature were used to populate the model. Drug acquisition, administra-
tion, and event costs were considered. RESULTS: Over 3 years, 61 additional pa-
tients reached their LDL-C goal in scenario 2, comparedwith scenario 1 (770 vs. 709,
respectively), at an increased cost of $637,000 ($1,714,000 vs. $1,077,000, respec-
tively). The additional permember permonth (PMPM) cost of scenario 2 to theMHC
plan was $0.02. When the cost of managing CV events was accounted for, the
budget impact decreased to $634,000. CONCLUSIONS: Although the model has
some limitations, it highlights the value of appropriate prescribing of statins. Ini-
tiating high-risk hyperlipidemic patients on rosuvastatinmay increase the number
of patients reaching LDL-C goals (defined in NCEP guidelines) at a relativelymodest
increase in PMPM cost to a MHC plan, despite the low cost of generic statins.
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OBJECTIVES: Ticagrelor (TG) is a new oral platelet inhibitor with improved thera-
peutic effect and safety profile than clopidogrel. Yet it is not listed in the public
hospital formulary of Hong Kong, hence suitable patients do not have general
access to it. A budget impact analysis would thus help provide evidence to assist
local budget holders in decision making processes. METHODS: A budget impact
model was built to allow assessment of the budgetary impact to the local health
care system from a government perspective if TG is introduced into the local mar-
ket. The scenarios adopted were world with andwithout TG. A hypothetical cohort
of 16,000 patients with acute coronary syndrome (ACS) was used as the population.
Proportion of ACS events was estimated using HK-specific values. Sources of drug
and DRGs costs were from the local public hospital authority as released in 2011.
Market shares of TG as compared to clopidogrel (branded) for world without and
with TG over a 5-year period were assumed to be 0% and 10-25% (with 5% incre-
ment/year) respectively. RESULTS: Over a 5-year period, the budget impact of
using TG was estimated to range from 1.18% (year-1) to 3.21% (year-5) if TG was
introduced. The actual extra cost per patient was estimated to range from
HKD423 (USD54, 1USD7.8HKD) in year-1 to HKD1,135 (USD146) in year-5. De-
terministic sensitivity analysis performed suggested that proportions of bleed-
ing between the 2 drugs and drug cost are the most influential variables. The
drug acqusition costs were partially offset by improved therapetic outcomes,
reduction in side effects and shortened hospital stay. CONCLUSIONS: Results of
the present budget impact analysis suggest that introducing TG into the market
of Hong Kong would only have minimal effect on the health care budget. Budget
holders should consider TG as an option to clopidogrel in view of its better
therapeutic effects and safety profile.
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OBJECTIVES:Todescribe and compare health resource utilization and related costs
of patients with chronic thromboembolic pulmonary hypertension (CTEPH) and
pulmonary arterial hypertension (PAH) in six European countries. METHODS: We
reviewed medical charts from patients diagnosed with CTEPH or PAH and treated
with PAH-specific therapy: Endothelin-receptor antagonists (ERA), prostacyclin an-
alogues (PA) or PDE5-inhibitors (PDEi). Data on demographic and clinical charac-
teristics, PAH-medication, and health resource utilization were retrospectively ab-
stracted from patients’ medical records at specialized PH treatment centers across
six European countries. Resource utilizationwas valued using country-specific unit
costs; descriptive statistical analyses were performed. RESULTS: Twenty one hos-
pitals documented 405 patients (120 in CTEPH and 285 in PAH). CTEPH patients
were older with a mean age of 67.5 12.1 years versus 55.3 15.6 years for PAH
patients. In the CTEPH group, 60% were female (PAH 74.4%) and both groups were
on average observed for 25.7months (SD 10.2). At baseline, 59.2% of CTEPH patients
received ERA (PAH 53%), 5.8% PA (PAH 5.0%), and 34.2% PDE5i (PAH 37.0%). CTEPH
patients experienced 1.8 2.2 hospitalizations per year accounting for 15.0 26.0
days in hospital, compared to PAH patients with 1.52.4 hospitalizations and 20.6
44.7 days, respectively. In both groups annual costs of PH medication was the
predominant cost factor averaging €37,346 23,183 in CTEPH and €38,840 29,072
in PAH, followed by hospitalizations (CTEPH €4,554 7,894, PAH €6,254 €13,571)
and concomitant medications (CTEPH €2,534  €2505, PAH €1,301  €1,514). Other
health care resource items only accounted for marginal additional costs in both
groups. CONCLUSIONS: These data show similar overall costs for patients with
PAHandCTEPH. Although, for CTEPHoff-label andwithout evidence from random-
ized trials, in both groups, PAH-specific medication was the predominant cost
factor. CTEPH patients tended to have higher costs for concomitant medication
whereas hospitalizations were more common in PAH.
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OBJECTIVES: Atrial Fibrillation (AF) greatly increases the risk of stroke. AF-related
stroke is associated with higher mortality, worse outcome and higher health care
cost, which is substantial for patients and society. Few studies, however, of the
costs of AF-related stroke were available in China. This study aimed to assess and
compare the hospital costs and length-of-stay in patients with AF and AF-related
stroke in China from payer’s perspective.METHODS:Data were extracted from the
BasicMedical Insurance Databases in 2010. 385 patientswere randomly selected by
stratified two-stage sampling. All information of patient demographic characters,
clinical and costs were collected for the analysis. The descriptive statistics was
used to describe patients’ demographic characters, the hospital stay and the hos-
pital costs. Univariate and multivariable analyses were also used in the data
analysis. RESULTS: Total 385 patients (mean age 70.6 years; 51.4% male) were
evaluated, 59.0% of patients with AF and 41.0% of patients with AF-related stroke.
The mean length-of-stay was 14.2 days (11.9 days AF and 17.5 days AF related
stroke; P 0.001); the mean total cost was 17630.42 (median: 9323.25, IQR: 5086.87-
20193.43): 17734.93 (median: 6891.92, IQR: 3898.78-20751.16) with AF and 17480.27
(median: 11975.32, IQR: 7863.3-19941.85)withAF-related stroke (P0.001). Themul-
tiple linear regressions showed that the hospital cost of AF-related stroke was 81%
higher than the hospital cost of AF. Patientswith basicmedical insurance for urban
employees had 39.6% higher costs than those with basic medical insurance for
urban residents (P0.001). Patients from tertiary hospitals had 97.8% higher costs
than those from primary hospitals; (P0.001) and patients frommunicipalities had
58.0% higher costs than those from prefecture-level cities; (P0.01).
CONCLUSIONS: Patients with AF-related stroke is associated with significantly
higher hospital costs compared with those with AF. It implied that stroke preven-
tion in AF may have potential cost savings.
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OBJECTIVES: The lack of data has presented a challenge to perform pharmacoeco-
nomic research in Asia. However, efforts have been made to make cost data avail-
able and this study presents newly available data from clinical costing databases in
Malaysia, Indonesia and the Philippines. The objective is to determine the length of
stay and treatment cost per episode of acutemyocardial infarction (MI).METHODS:
A117V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
